Detalhe da pesquisa
1.
Neonatal rotavirus vaccine (RV3-BB) immunogenicity and safety in a neonatal and infant administration schedule in Malawi: a randomised, double-blind, four-arm parallel group dose-ranging study.
Lancet Infect Dis
; 22(5): 668-678, 2022 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35065683
2.
Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial.
Lancet HIV
; 6(4): e230-e239, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30885692
3.
A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef Vaccine in Healthy HIV-Uninfected African Adults.
PLoS One
; 10(5): e0125954, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25961283
4.
Non-immunogenicity of overlapping gag peptides pulsed on autologous cells after vaccination of HIV infected individuals.
PLoS One
; 8(10): e74389, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24124451
5.
A randomised, placebo-controlled, first-in-human study of a novel clade C therapeutic peptide vaccine administered ex vivo to autologous white blood cells in HIV infected individuals.
PLoS One
; 8(9): e73765, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24069230
6.
Dimethyl sulfoxide (DMSO) exposure to human peripheral blood mononuclear cells (PBMCs) abolish T cell responses only in high concentrations and following coincubation for more than two hours.
J Immunol Methods
; 356(1-2): 70-8, 2010 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-20156444